Company: Chaperone Therapeutics
Location: US-North Carolina
Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s disease, Huntington’s disease, Parkinson’s Disease and other conditions.
Mechanism Type: Proteostasis, Protein misfolding modulator
Mechanism: Chaperone Therapeutics is developing small molecules that aim to activate HSF1, a key modulator of protein folding and stress response pathways. The approach aims to lower neuronal stress by reducing the buildup of misfolded proteins.
U.S. Status for ALS: Preclinical
 Chaperone Therapeutics and ALS Therapy Development Institute Enter into Research Partnership. ChaperoneTherapeutics, 10 Aug 2015. Accessed 9 Mar 2016 from http://www.chaperonetherapeutics.com/wp-content/uploads/2015/08/Chaperone-Therapeutics-and-ALS-TDI-press-release.pdf.
Last updated February 8th, 2018